INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fortress Biotech, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fortress Biotech, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm PR Newswire LOS more...
CELSION CORPORATION ANNOUNCES $35 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
LAWRENCEVILLE, NJ, Jan. 22, 2021 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 25,925,925 shares of more...
aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases
Poster to be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition. Research approach led to the identification of target receptors for two tRNA synthetases and further validates company’s more...
Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT Meetings Digital Experience
LA JOLLA, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that interim data from the Phase 1b/2 more...
Immutep Quarterly Activities Report
Highlights Encouraging efti data reported from phase IIb AIPAC and phase II TACTI-002 clinical trials TACTI-002 study expanded in lung cancer New phase II trial in head and neck cancer announced EOC Pharma starts new more...
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued
Immutep’s Collaboration and Exclusive License with GSK Remains in Place Sydney, AUSTRALIA, Jan. 22, 2021 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments more...
SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger
NEW YORK, NY / ACCESSWIRE / January 21, 2021 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities more...
ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Fortress Biotech, Inc. Investors of Important January 26 Deadline in Securities Class Action – FBIO
NEW YORK, Jan. 21, 2021 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and October 9, more...
SHAREHOLDER ALERT: WeissLaw LLP Reminds CPAH, CATM, ANCN and GNBF Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: WeissLaw LLP Reminds CPAH, CATM, ANCN and GNBF Shareholders About Its Ongoing Investigations PR Newswire NEW YORK , Jan. 21, 2021 /PRNewswire/ — If you own shares in any of the companies listed more...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of INFO, PS, CATM, and ANCN Mergers
WILMINGTON, Del., Jan. 21, 2021 (GLOBE NEWSWIRE) — Rigrodsky Law, P.A. announces that it is investigating: IHS Markit Ltd. (NYSE: INFO ) regarding possible breaches of fiduciary duties and other violations of law related to more...